CymaBay Therapeutics Inc (CBAY) Holdings Trimmed by MetLife Investment Advisors LLC

MetLife Investment Advisors LLC trimmed its position in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 35.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,178 shares of the biopharmaceutical company’s stock after selling 15,542 shares during the quarter. MetLife Investment Advisors LLC’s holdings in CymaBay Therapeutics were worth $222,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Pearl River Capital LLC acquired a new position in CymaBay Therapeutics in the 4th quarter valued at about $74,000. D. E. Shaw & Co. Inc. acquired a new position in CymaBay Therapeutics in the 4th quarter valued at about $82,000. PNC Financial Services Group Inc. boosted its holdings in CymaBay Therapeutics by 23.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 2,460 shares during the last quarter. Citigroup Inc. boosted its holdings in CymaBay Therapeutics by 17.7% in the 4th quarter. Citigroup Inc. now owns 19,966 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 3,000 shares during the last quarter. Finally, LPL Financial LLC acquired a new position in CymaBay Therapeutics in the 3rd quarter valued at about $282,000. Institutional investors own 98.00% of the company’s stock.

CBAY has been the topic of several recent analyst reports. Piper Jaffray Companies set a $30.00 target price on shares of CymaBay Therapeutics and gave the company a “buy” rating in a report on Friday, March 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 target price on shares of CymaBay Therapeutics in a report on Friday, February 1st. Roth Capital reissued a “buy” rating on shares of CymaBay Therapeutics in a research note on Tuesday, February 19th. Oppenheimer set a $18.00 price target on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research note on Friday, February 15th. Finally, BidaskClub raised shares of CymaBay Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, February 27th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $19.63.

In other news, Director Carl Goldfischer sold 11,675 shares of the business’s stock in a transaction that occurred on Thursday, February 7th. The shares were sold at an average price of $9.02, for a total value of $105,308.50. Following the sale, the director now directly owns 2,335 shares of the company’s stock, valued at approximately $21,061.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.50% of the stock is currently owned by insiders.

CymaBay Therapeutics stock opened at $12.07 on Friday. CymaBay Therapeutics Inc has a 1 year low of $6.31 and a 1 year high of $15.00.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/04/21/cymabay-therapeutics-inc-cbay-holdings-trimmed-by-metlife-investment-advisors-llc.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Further Reading: What Are Cryptocurrencies?

Want to see what other hedge funds are holding CBAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CymaBay Therapeutics Inc (NASDAQ:CBAY).

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.